2. Search Result
Search Result
No matches for "

55336

" within the MedChemExpress (MCE) catalog. Here are the results you might be looking for.

3

Inhibitors & Agonists

1

Inhibitory Antibodies

3

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156794
    Enzomenib

    DSP-5336

    		 Epigenetic Reader Domain FLT3 Cancer
    Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations .
    Enzomenib
  • HY-P990874
    Anti-HIV gp120 Antibody (55-36)

    		HIV Infection
    Anti-HIV gp120 Antibody (55-36) is a kind of mouse IgG1 κ chimeric antibody, targeting to human HIV gp120. Anti-HIV gp120 Antibody (55-36) reacts with human immunodeficiency virus (HIV) envelope glycoprotein 120 (gp120). Anti-HIV gp120 Antibody (55-36) can be used for the research of HIV infection .
    Anti-HIV gp120 Antibody (55-36)
  • HY-156794A
    Enzomenib enantiomer

    DSP-5336 enantiomer

    		 Drug Isomer FLT3 Epigenetic Reader Domain Cardiovascular Disease Cancer
    Enzomenib enantiomer (DSP-5336 enantiomer) is an enantiomer of Enzomenib (HY-156794). Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations .
    Enzomenib enantiomer

Inquiry Online

Submit your filled information, we will contact you soon.

Salutation: * Country or Region:
* Applicant Name: * Organization Name:
* Department:    
* Email Address: * Product Name:
Cat. No.: * Requested quantity:
* Phone Number:    
Remarks:

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: